{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:43:00Z","timestamp":1791664980806,"version":"4.3.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oral propranolol is the first-line treatment for problematic infantile hemangiomas (IHs) requiring systematic therapy. Several retrospective studies have reported the successful treatment of facial IHs with propranolol. In this study, the authors conducted a prospective trial to evaluate the long-term outcomes of oral propranolol use in patients with facial IHs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The primary outcome was the clinical response 4 years after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 272 patients were analyzed, including 38 patients (14.0%) with ulcerated IHs. Four years after treatment, propranolol treatment had resulted in no\/minimal sequelae in 232 patients (85.3%). A total of 265 patients (97.4%) reported a durable response to propranolol therapy. Major rebound occurred in 16.9% of patients after propranolol discontinuation. Additional surgery and laser treatment were required in 8.1% and 8.8% of patients, respectively. Logistic regression analyses revealed that age 3 months or older (95% CI, 1.488 to 31.023;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013), nasal IH (95% CI, 2.143 to 97.571;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006), and hemangioma ulceration (95% CI, 2.673 to 49.034;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001) were independent factors predictive of long-term severe\/significant sequelae. Segmental subtype (95% CI, 2.081 to 45.597;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004), mixed IH (95% CI, 3.249 to 26.841;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), and lip IH (95% CI, 2.224 to 92.278;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005) were independent risk factors for major rebound.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this large cohort of patients with facial IHs, propranolol treatment was effective and induced no\/minimal sequelae at 4 years after treatment. However, long-term severe\/significant sequelae and major rebound after propranolol treatment remain challenges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/prs.0000000000012186","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T17:00:10Z","timestamp":1746550810000},"page":"142-149","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Long-Term Outcomes of Oral Propranolol for Facial Infantile Hemangioma"],"prefix":"10.1097","volume":"157","author":[{"given":"Jiangyuan","family":"Zhou","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuru","family":"Lan","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Qiu","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiying","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuepeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Department of Critical Care Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, West China Hospital of Sichuan University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery and Center of Children Medicine, Sichuan Academy of Medical Sciences\/Sichuan Provincial People\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Sichuan Women and Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiteng","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Chengdu Women and Children\u2019s Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Vascular and Interventional Radiology, West China Second University Hospital, Sichuan University."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Pediatric Intensive Care Unit, Department of Critical Care Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ji","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Pediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"R1-20251222","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/bjd.12804","article-title":"Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies.","volume":"170","author":"Munden","year":"2014","journal-title":"Br J Dermatol"},{"key":"R2-20251222","doi-asserted-by":"crossref","first-page":"pbac006","DOI":"10.1093\/pcmedi\/pbac006","article-title":"Infantile hepatic hemangiomas: looking backwards and forwards.","volume":"5","author":"Gong","year":"2022","journal-title":"Precis Clin Med"},{"key":"R3-20251222","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/TCRM.S291059","article-title":"Clinical features of segmental infantile hemangioma: a prospective study.","volume":"17","author":"Qiu","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"R4-20251222","doi-asserted-by":"crossref","first-page":"e20183475","DOI":"10.1542\/peds.2018-3475","article-title":"Clinical practice guideline for the management of infantile hemangiomas.","volume":"143","author":"Krowchuk","year":"2019","journal-title":"Pediatrics"},{"key":"R5-20251222","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/jamaoto.2021.0454","article-title":"Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial.","volume":"147","author":"Ji","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"R6-20251222","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma.","volume":"372","author":"Leaute-Labreze","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-20251222","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archoto.2011.55","article-title":"Propranolol as first-line treatment of head and neck hemangiomas.","volume":"137","author":"Fuchsmann","year":"2011","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R8-20251222","doi-asserted-by":"crossref","first-page":"106120","DOI":"10.1016\/j.ijscr.2021.106120","article-title":"The effectiveness of oral propranolol for infantile hemangioma on the head and neck region: a case series.","volume":"84","author":"Kreshanti","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"R9-20251222","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/ped.13109","article-title":"Low-dose propranolol for infantile hemangioma of the head and neck: analysis of 23 consecutive patients.","volume":"59","author":"Ren","year":"2017","journal-title":"Pediatr Int"},{"key":"R10-20251222","doi-asserted-by":"crossref","first-page":"21670","DOI":"10.1038\/srep21670","article-title":"Pharmacological therapies for infantile hemangiomas: a clinical study in 853 consecutive patients using a standard treatment algorithm.","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"R11-20251222","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaad.2023.12.036","article-title":"Clinical features of rapid involuting congenital hemangioma: a prospective study.","volume":"90","author":"Qiu","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R12-20251222","doi-asserted-by":"crossref","first-page":"e20151754","DOI":"10.1542\/peds.2015-1754","article-title":"Rebound growth of infantile hemangiomas after propranolol therapy.","volume":"137","author":"Shah","year":"2016","journal-title":"Pediatrics"},{"key":"R13-20251222","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/PRS.0b013e318208d2ac","article-title":"Untreated hemangiomas: growth pattern and residual lesions.","volume":"127","author":"Bauland","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R14-20251222","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/JS9.0000000000000324","article-title":"Indications for surgical resection of complicated infantile hemangiomas in the beta-blocker\u2019s era: a single-institution experience from a retrospective cohort study.","volume":"109","author":"Beqo","year":"2023","journal-title":"Int J Surg"},{"key":"R15-20251222","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/1346-8138.14853","article-title":"Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: a long-term follow-up study.","volume":"46","author":"Yu","year":"2019","journal-title":"J Dermatol"},{"key":"R16-20251222","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/SAP.0000000000003206","article-title":"Does oral propranolol improve the final outcome of all involuted infantile hemangiomas? A matched retrospective comparative study.","volume":"89","author":"Chang","year":"2022","journal-title":"Ann Plast Surg"},{"key":"R17-20251222","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjd.13388","article-title":"The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action.","volume":"172","author":"Ji","year":"2015","journal-title":"Br J Dermatol"},{"key":"R18-20251222","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/PRS.0000000000011532","article-title":"Has propranolol eradicated the need for surgery in the management of infantile hemangioma?","volume":"155","author":"Coulie","year":"2025","journal-title":"Plast Reconstr Surg"},{"key":"R19-20251222","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PRS.0b013e31825dc129","article-title":"Infantile hemangioma: clinical assessment of the involuting phase and implications for management.","volume":"130","author":"Couto","year":"2012","journal-title":"Plast Reconstr Surg"},{"key":"R20-20251222","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/pde.15198","article-title":"Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.","volume":"40","author":"Leaute-Labreze","year":"2023","journal-title":"Pediatr Dermatol"},{"key":"R21-20251222","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1542\/peds.2011-3683","article-title":"Early growth of infantile hemangiomas: what parents\u2019 photographs tell us.","volume":"130","author":"Tollefson","year":"2012","journal-title":"Pediatrics"},{"key":"R22-20251222","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1525-1470.2010.01379.x","article-title":"Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study.","volume":"28","author":"Zvulunov","year":"2011","journal-title":"Pediatr Dermatol"},{"key":"R23-20251222","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00431-020-03872-5","article-title":"Recurrence rate of infantile hemangioma after oral propranolol therapy.","volume":"180","author":"Frongia","year":"2021","journal-title":"Eur J Pediatr"},{"key":"R24-20251222","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/bjd.12432","article-title":"Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.","volume":"169","author":"Ahogo","year":"2013","journal-title":"Br J Dermatol"},{"key":"R25-20251222","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1542\/peds.2007-2767","article-title":"Growth characteristics of infantile hemangiomas: implications for management.","volume":"122","author":"Chang","year":"2008","journal-title":"Pediatrics"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000012186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T15:00:38Z","timestamp":1766415638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000012186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000012186","relation":{},"ISSN":["0032-1052","1529-4242"],"issn-type":[{"value":"0032-1052","type":"print"},{"value":"1529-4242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}